Skip to content
Stock screener

CUE Cue Biopharma, Inc. stock chart & analysis

Conviction 45HealthcareScan · Wed, Nov 18, 2026

Cue Biopharma, Inc. (CUE) closed at $4.73 (+67.14%) on Nov 18, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 25, RS Rating 17, -89.6% from its 52-week high, -48.4% year to date. Sector: Healthcare · Pharmaceutical Preparations.

CUE$4.73+67.14%
ResistanceSupportVol 14Insider buyInsider sell
Loading chart…
Cue Biopharma, Inc.Pharmaceutical Preparationswww.cuebiopharma.com ↗
Price4.73
Change+67.14%
Gap+21.20%
Rel volume31.62×
Avg volume897.96K
Avg $ vol5.69M
SMA 2017.38
SMA 5022.61
SMA 20021.53
Price vs 50-79.08%
Price vs 200-78.03%
MA stackmixed
50/200 cross—
Supertrenddown · 13.25
RSI (14)25
MACD hist-1.34
MACD crossbear · 2d
Stoch %K / %D10 / 5
ADX (14)21
+DI / −DI11 / 45
RSI divergenceBullish
MACD divergenceBullish
ATR %63.04%
ADR %29.98%
52w high45.50
52w low2.83
From 52w high-89.60%
Above 52w low+67.14%
New 52w highNo
SqueezeOff
Bollinger width111.45%
%B-0.15
Donchian pos9.66%
Donchian high22.49
Donchian low2.83
AVWAP (52w high)18.19
vs AVWAP high-73.99%
AVWAP (52w low)4.84
vs AVWAP low-2.32%
OBV trendUp
Chaikin MF (20)0.37
Today vs 20d31.62×
Avg vol (14d)1.23M
Avg vol (20d)897.96K
Avg $ vol (20d)5.69M
Market cap—
RS Rating17 / 99
RS 3m (vs SPY)-76.55%
RS 6m (vs SPY)-75.37%
RS line new highNo
Trend template3/8
Technical rank3.2
1 week-74.65%
1 month-72.24%
3 months-80.78%
6 months-76.85%
1 year-72.53%
YTD-48.37%
P/E-0.91
P/B0.63
P/S0.89
P/FCF-1.11
EPS-0.2800
Div yield—
ROE-69.28%
ROA-39.55%
Debt/Eq0.00
Current3.38
EV/EBITDA1.31
Gross margin—
Net margin-96.85%
Rev growth195.75%
EPS growth34.60%
Price target—
Target upside—
Analyst rating—
Institutional—
Ent. value-33.51M
Revenue132K
Net income-50.02M
Gross profit—
Free cash flow-21.86M
IndustryPharmaceutical Preparations
ExchangeNasdaq
Shares out4.2M
Employees29
ListedTue, Jan 2, 2018
Free float—
Float %—
Short interest—
Days to cover—
Short volume—
Squeeze score—
Next earnings—
EPS forecast—
Last EPS vs est—
Last surprise—
Setup gradeD
Conviction45 / 100
Pattern quality—
Tech rank3.2 / 100
Group rank14 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance29.00
Support16.40
Days since event—
Candle confirm—

Financials as of Wed, Sep 30, 2026 · quarterly.

CUE technical analysis

Trend

CUE's moving averages are mixed — no clean uptrend or downtrend. It closed 79.1% below the 50-day ($22.61) and 78.0% below the 200-day ($21.53). ADX(14) at 21 points to a moderate trend. It meets 3 of 8 trend-template criteria.

Momentum

RSI(14) is 25, in oversold territory. MACD crossed below its signal line 2 sessions ago. A bullish RSI divergence is in place. A bullish MACD divergence is in place. Its RS Rating of 17 puts its weighted 12-month performance ahead of about 17% of the US market.

Volume and volatility

Volume on the latest session ran 31.6× its 20-day average. It trades about $5.7M a day on average. ATR(14) is $2.98, 63.0% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (0.37) shows accumulation.

Key levels

The chart pattern's support is $16.40 and its resistance $29.00. The 52-week range is $2.83 to $45.50; price is 89.6% below the high and 67.1% above the low. The VWAP anchored at the 52-week high is $18.19, above price.

Performance

CUE returned -74.7% (1 week), -72.2% (1 month), -80.8% (3 months), -76.8% (6 months), -72.5% (1 year), -48.4% (year to date).

About Cue Biopharma, Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

Pharmaceutical Preparations · Listed 2018 · 29 employees

Insider activity

SEC Form 4 transactions in CUE · open-market 5 sells

InsiderSideShares
Garzone Pamela
Director · Common Stock · 2026-07-09
Grant18.9K
Sarraf Pasha
Director · Common Stock · 2026-07-09
Grant18.4K
Meluzio Michael Vincent
VP, Prin. Accounting Officer · Common Stock · 2026-08-13
Exercise13.65K
Ray Sumita
Chief Legal Compliance Officer · Common Stock · 2026-08-13
Exercise18.2K
Ray Sumita
Chief Legal Compliance Officer · Common Stock · 2026-08-13
Sell2.38K
Ray Sumita
Chief Legal Compliance Officer · Common Stock · 2026-08-13
Sell6.44K
Ray Sumita
Chief Legal Compliance Officer · Common Stock · 2026-08-13
Sell4
Ray Sumita
Chief Legal Compliance Officer · Common Stock · 2026-08-13
Exercise18.2K
Meluzio Michael Vincent
VP, Prin. Accounting Officer · Common Stock · 2026-08-13
Sell1.52K
Meluzio Michael Vincent
VP, Prin. Accounting Officer · Common Stock · 2026-08-13
Sell4.11K

SEC filings

EDGAR filings in CUE · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.